Transcatheter aortic valve implantation is the treatment of choice for inoperable patients and an alternative for high-risk patients with severe aortic stenosis, with expanding indications expected.
This review highlights the established role of TAVI in high-risk patients and its expanding indications into intermediate-risk and complex anatomical scenarios.
Transcatheter aortic valve implantation (TAVI), also known as transcatheter aortic valve replacement, is increasingly performed worldwide and is a technology that is here to stay. It has become the treatment of choice for inoperable patients and an alternative option for patients at high surgical risk with severe aortic stenosis. Early results of TAVI in intermediate-risk patients appear promising although larger randomized trial results are awaited before the widespread adoption of this technology in this big pool of patients. In patients with bicuspid aortic stenosis and degenerated surgical bioprostheses, TAVI has been shown to be feasible and relatively safe, though certain important considerations remain. Indications for TAVI are likely to grow as newer generation and improved devices and delivery systems become available.
Chiam et al. (Fri,) conducted a review in Severe aortic stenosis. Transcatheter aortic valve implantation (TAVI) was evaluated. Transcatheter aortic valve implantation is the treatment of choice for inoperable patients and an alternative for high-risk patients with severe aortic stenosis, with expanding indications expected.